Acute leukemias of ambiguous lineage (ALAL) are rare hematologic malignancies with poor outcomes. Retrospective studies have suggested that acute lymphoblastic leukemia (ALL) regimens are more effective than acute myeloid leukemia (AML) regimens. We retrospectively examined the effectiveness of the widely-used adult ALL regimen hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyperCVAD) as initial therapy in patients with ALAL at five academic institutions. Twenty-five patients were identified, including 23 with mixed phenotype acute leukemia (MPAL) and two with acute undifferentiated leukemia. Five of 8 tested (63%) had FLT3-ITD and 3 of 25 (12%) were Philadelphia chromosome-positive. The complete remission (CR) rate was 76%, with CR with incomplete count recovery (CRi) in an additional 8%, for an overall response rate of 84%. Median number of cycles to CR/CRi was 1. There were no deaths in the first 30 days. Of the 21 patients achieving CR or CRi, 14 (66%) proceeded to allogeneic hematopoietic stem cell transplantation. With a median follow-up time of 31.6 months, median overall survival for the entire cohort was not reached, and the estimated 2-year survival was 63%. HyperCVAD can be considered an effective and tolerable front-line regimen for patients with ALAL, and warrants further prospective study.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Van-Den-Ancker W, Terwijn M, Westers TM et al (2010) Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification. Leukemia 24:1392–1396
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
Xu XQ, Wang JM, Lü SQ et al (2009) Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. Haematologica 94:919–927
Khan M, Siddiqi R, Naqvi K (2018) An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL). Ann Hematol 97:945–953
Steensma DP (2011) Oddballs: acute leukemias of mixed phenotype and ambiguous origin. Hematol Oncol Clin North Am 25:1235–1253
Matutes E, Pickl WF, Veer MVNT et al (2011) Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 117:3163–3171
Tian H, Xu Y, Liu L, Yan L, Jin Z, Tang X, Han Y, Fu Z, Qiu H, Sun A, Wu D (2016) Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. Leuk Res 45:40–46
Guru Murthy GS, Dhakal I, Lee JY, Mehta P (2017) Acute leukemia of ambiguous lineage in elderly patients – analysis of survival using surveillance epidemiology and end results-Medicare Database. Clin Lymphoma Myeloma Leuk 17:100–107
Maruffi M, Sposto R, Oberley MJ, Kysh L, Orgel E (2018) Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia 32:1515–1528
Wolach O, Stone RM (2016) How I treat mixed-phenotype acute leukemia. Blood 125:2477–2486
Wolach O, Stone RM (2017) Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. Curr Opin Hematol 24:139–145
Kantarjian H, Thomas D, O’Brien S et al (2004) Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101:2788–2801
Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547–561
NCCN Clinical Practice Guidelines in Oncology, Acute Lymphoblastic Leukemia, Version 2.2019. In: NCCN Website. https//www.nccn.org/professionals/physician_gls/pdf/all.pdf. Updat. May 15, 2019. Accessed Novemb 9, 2019. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed 9 Nov 2019
Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642–4649
Al-Seraihy AS, Owaidah TM, Ayas M et al (2009) Clinical characteristics and outcome of children with biphenotypic acute leukemia. Haematologica 94:1682–1690
Hrusak O, De Haas V, Stancikova J et al (2018) International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood 132:264–276
Orgel E, Alexander TB, Wood BL, Kahwash SB, Devidas M, Dai Y, Alonzo TA, Mullighan CG, Inaba H, Hunger SP, Raetz EA, Gamis AS, Rabin KR, Carroll AJ III, Heerema NA, Berman JN, Woods WG, Loh ML, Zweidler-McKay PA, Horan JT, for the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force (2020) Mixed-phenotype acute leukemia: a cohort and consensus research strategy from the children’s oncology group acute leukemia of ambiguous lineage task force. Cancer 126:593–601
Weinberg OK, Seetharam M, Li R et al (2014) Mixed phenotype acute leukemia a study of 61 cases using world health organization and european group for the immunological classification of leukaemias criteria. Am J Clin Pathol 142:803–808
Yan L, Ping N, Zhu M, Sun A, Xue Y, Ruan C, Drexler HG, MacLeod RAF, Wu D, Chen S (2012) Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica 97:1708–1712
Deffis-Court M, Alvarado-Ibarra M, Ruiz-Argüelles GJ, Rosas-López A, Barrera-Lumbreras G, Aguayo-González Á, López-Karpovitch X, López-Hernández M, Velázquez-Sánchez de Cima S, Zamora-Ortiz G, Crespo-Solís E (2014) Diagnosing and treating mixed phenotype acute leukemia: a multicenter 10-year experience in México. Ann Hematol 93:595–601
Shimizu H, Saitoh T, Machida S, Kako S, Doki N, Mori T, Sakura T, Kanda Y, Kanamori H, Miyawaki S, Okamoto S, Kanto Study Group for Cell Therapy (KSGCT) (2015) Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. Eur J Haematol 95:455–460
Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P (2012) Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol 87:472–478
Stock W, La M, Sanford B et al (2008) What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children’s cancer group and cancer and leukemia group B studies. Blood 112:1646–1654
Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A, Rowe J, Webb D (2007) Adolescents with acute lymphoblastic leukaemia: outcome on UK National Paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 48:254–261
Boissel N, Auclerc MF, Lhéritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela JM, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C, Boiron JM, Pautas C, Michel G, Fière D, Leverger G, Dombret H, Baruchel A (2003) Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21:774–780
Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM (2016) Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol 91:819–823
Munker R, Brazauskas R, Wang HL, de Lima M, Khoury HJ, Gale RP, Maziarz RT, Sandmaier BM, Weisdorf D, Saber W, Center for International Blood and Marrow Transplant Research (2016) Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia. Biol Blood Marrow Transplant 22:1024–1029
Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A (2017) Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the acute leukemia working party of the EBMT. Haematologica 102:2134–2140
Heesch S, Neumann M, Schwartz S, Bartram I, Schlee C, Burmeister T, Hänel M, Ganser A, Heuser M, Wendtner CM, Berdel WE, Gökbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD (2013) Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. Ann Hematol 92:747–758
Conflict of interest
KS has been on advisory boards for Takeda, Bristol-Myers Squibb, and Novartis; reports honoraria from Astellas and Stemline; and has received research funding from Incyte. ESW has had an advisory role with Abbvie, Astellas, Daiichi Sankyo, Dava Oncology/Arog, Genentech, Jazz, Kite Pharmaceuticals, Kura Oncology, Macrogenics, Pfizer, PTC Therapeutics, and Stemline and has been a speaker for Stemline and Pfizer. All other authors report no relevant conflicts of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The respective Institutional Review Boards at each study center approved this study. As this was a retrospective study, informed consent could not be obtained from all patients included in the study.
Consent to participate
Consent for publication
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Duong, V.H., Begna, K.H., Kashanian, S. et al. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. Ann Hematol 99, 2119–2124 (2020). https://doi.org/10.1007/s00277-020-04179-z
- Acute leukemia of ambiguous lineage
- Mixed phenotype acute leukemia